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Abstract
Background: Non-pharmacological treatment (NPT) is a useful treatment option in the management of hip or knee 
osteoarthritis. To our knowledge however, no studies have investigated the effect of NPT in patients with generalized 
osteoarthritis (GOA). The primary aim of this study is to compare the effectiveness of two currently existing health care 
programs with different intensity and mode of delivery on daily functioning in patients with GOA. The secondary 
objective is to compare the cost-effectiveness of both interventions.
Methods/Design: In this randomized, single blind, clinical trial with active controls, we aim to include 170 patients 
with GOA. The experimental intervention consist of six self-management group sessions provided by a multi-
disciplinary team (occupational therapist, physiotherapist, dietician and specialized nurse). The active control group 
consists of two group sessions and four sessions by telephone, provided by a specialized nurse and physiotherapist. 
Both therapies last six weeks. Main study outcome is daily functioning during the first year after the treatment, assessed 
on the Health Assessment Questionnaire. Secondary outcomes are health related quality of life, specific complaints, 
fatigue, and costs. Illness cognitions, global perceived effect and self-efficacy, will also be assessed for a responder 
analysis. Outcome assessments are performed directly after the intervention, after 26 weeks and after 52 weeks.
Discussion: This article describes the design of a randomized, single blind, clinical trial with a one year follow up to 
compare the costs and effectiveness of two non-pharmacological interventions with different modes of delivery for 
patients with GOA.
Trial registration: Dutch Trial Register NTR2137
Background
Osteoarthritis (OA), the most prevalent rheumatic disor-
der affecting the musculoskeletal system, has a major
impact on functioning and independence of the elderly.
In general, one distinguishes between four subgroups of
peripheral OA: 1. knee, 2. hip, 3. hand and 4 generalized
OA (GOA) [1]. Clinically, 10-15% of adults over 60 have
symptomatic knee OA [2-5] and symptomatic hip OA
occurs in 1-4% of all adults [3]. Symptomatic hand OA
occurs in 10-15% of the elderly [6] and GOA in 27% of the
patients with hip or knee OA [7].
Non-pharmacological treatment (NPT) is considered
to be important in the management of OA in order to
reduce the impact of OA on pain and physical function-
ing [8]. Current OA research on NPT-options, focuses
mainly on the hip and knee joint [9]. An abundance of
research literature illustrates that NPT is a useful treat-
ment option in the management of hip or knee OA [9].
The initial focus of NPT should lie on self-management
and patient-driven treatments, rather than on passive
therapies delivered by allied health professionals [8]. Pro-
vision of information and patient education about the
objectives of treatment and the importance of changes in
lifestyle, exercise, pacing of activities, weight reduction
a n d  o t h e r  m e a s u r e s  t o  u n l o a d  d a m a g e d  j o i n t s  i s  s u p -
ported by two meta-analyses [10,11] on the efficacy of
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non-pharmacological interventions in chronic diseases.
Increasing the functional capacity [12-14] and encourag-
ing the patient to undertake and maintain regular exer-
cise [15] have also been found effective.
There is lack of evidence concerning the optimum
mode of care delivery. The more traditional face-to-face
contact is by far the most evaluated type of therapy deliv-
ery. However, telephone contact aimed at promoting self-
care appears to be more cost-efficient [16] and has also
been associated with improvements in joint pain [17,18]
and physical function [18] for up to a year in patients with
knee OA. Moreover, in a recent study by Eakon et al
(2009) telephone counselling was suggested a feasible
mode of delivering lifestyle interventions to patients with
chronic conditions and demonstrated modest improve-
ments in diet and physical activity [19].
To our knowledge, only one study investigated the
effect of a non-pharmacological intervention in the man-
agement of GOA [20]. However, in this study all GOA-
patients recently underwent major joint replacement,
therefore the results of this study cannot be generalized
to a population in which joint replacement is not (yet) an
option. Taking into account a. the extensive body of liter-
ature on NPT for hip or knee OA, b. the substantial group
of patients and c. the fact OA in multiple joints is more
disabling than in one joint [21-23], it is remarkable that
research on the efficacy of NPT options in GOA is hith-
erto neglected.
Considering the latter, we infer that the development
and evaluation of a treatment programme is warranted.
To do so, we installed an expert group consisting of a
physiotherapist, an occupational therapist, a specialized
nurse, a rheumatologist and two researchers, all of whom
have extensive experience with GOA patients. Conse-
quently, the expert group systematically conceptualized a
definition of GOA and a treatment programme tailored
to the needs of patients with GOA and based on recom-
mendations for the management of hip and knee OA [8,9]
and on the clinical experience of the health care provid-
ers. This resulted in a best-evidence, multi-disciplinary
treatment programme. Since there is no information
about the optimal treatment intensity and mode of deliv-
ery, we decided to compare the effectiveness of a fully
supervised multi-disciplinary program to an active con-
trol [24] (i.e. a telephone monitored program combined
with two supervised contact moments). Due to the com-
plex nature of GOA and the fact that guidelines for hip
and knee OA recommend multiple NPT modalities, both
interventions are multi-disciplinary [8]. We hypothesize
t h a t  b o t h  p r o g r a m m e s  h a v e  b e n e f i c i a l  e f f e c t s  o n  t h e
patients' quality of life and ability to cope with their dis-
ease, however we expect the face-to-face programme to
be superior with respect to daily functioning to the tele-
phone programme.
The primary aim of this study is to compare the effec-
tiveness of a supervised multi-disciplinary programme to
an active control on daily functioning in patients with
GOA during the first year after treatment. Secondary
aims of the study are to investigate the short-term effects
of interventions and to compare the cost-effectiveness of
both interventions.
Methods/Design
A pragmatic randomized, single blind, clinical, superior-
ity trial with active controls will be used to study the
aforementioned aims. The study will be performed at the
outpatient rheumatology departments of the Sint
Maartenskliniek Hospitals in the cities of Woerden and
Nijmegen in The Netherlands. Both centres have piloted
the interventions and in both centres, rooms well
equipped for group based treatments are available.
Patients - referred by their rheumatologist to the outpa-
tient department for multi-disciplinary NPT - eligible for
both the GOA health care program and the trial are
informed about the trial. Subsequently, consenting
patients are randomly allocated to one of the two groups
and followed by questionnaires for a total of 52 weeks
(figure 1).
The trial has been reviewed by the Institutional Review
Board of the University Medical Centre Nijmegen (proto-
col number 2009/290) and they concluded that the study
did not fall within the remit of the Medical Research
Involving Human Subjects Act. So the study can be car-
ried out (in the Netherlands) without an approval by an
accredited ethical board.
Eligibility Criteria
Men and women (≥ 18 years old) are eligible to enter the
trial if they are diagnosed with GOA (see our definition in
the following paragraph), motivated to alter their lifestyle
(assessed by a standardized set of questions), willing to
participate in a group and able to comply with the
planned time schedule of both treatment conditions.
Patients are excluded when they are 1. awaiting surgery,
2. already participated unsuccessfully in a self-manage-
ment program, 3. are considered not to be able to partici-
pate in a group due to limited psychological functioning
(on the basis of clinical judgment of a psychologist), 4. are
illiterate, 5. are not capable of communicating in Dutch
or 6. are incapable of coming to the hospital.
From the patients who were in principle eligible consid-
ering the in- and exclusion criteria but decided not to
participate in the study , baseline demographics (ie. age
and sex) will be gathered, to assess possible selection bias.
Definition of GOA
In the abovementioned inclusion criteria we mentioned
that patients must be diagnosed with GOA. However, noHoogeboom et al. BMC Musculoskeletal Disorders 2010, 11:142
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uniform GOA definition is available in the literature. A
pragmatic literature search elicited numerous definitions
for GOA [7,25-33], mainly used in genetic studies and for
the greater part based on patterns of distribution of joints
with radiological changes.
In clinical practice the term GOA refers to the combi-
nation of clinical symptoms and radiographic changes in
multiple joints which can be attributed to OA as obtain-
ing a full picture of radiological changes in all joints is not
feasible nor desirable in clinical practice. For the purpose
Figure 1 Overview of the study design. An overview of the study design showing recruitment, assessments, treatment groups, follow-up and out-
come assessments.
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of this project we formulated a pragmatic definition of
GOA based upon literature findings and on the basis of
consensus of several clinicians and health professionals
with experience in patients with GOA. In our definition
signs and symptoms are combined with radiological
changes. In this project a patient is defined as having
GOA if he or she complies with the following three con-
ditions:
a. experiencing complaints in three or more groups of 
joints, and;
b. having at least two objective signs that indicate OA 
in at least two joints (objective signs indicating OA 
are malalignment, palpable osteophytes/nodules, 
crepitations over the full range of motion, and limited 
range of motion or radiographic signs including the 
presence of joint space narrowing and/or osteo-
phytes, and;
c. is limited in daily functioning (Health Assessment 
Questionnaire score [34] > 0.5).
Interventions
During a six-week treatment period, patients will receive
one of the following two treatment programs:
- Interdisciplinary, group-based, self-management 
program (experimental intervention);
- Telephone-based, self-management program (active 
control).
Both pilot tested interventions were developed from a
clinical and pragmatic perspective, meaning that both
interventions had to be useful and feasible in clinical
practice. This resulted in two, for patients and health care
providers satisfactory, interventions. However, from a
research perspective lack of contrast between both inter-
ventions might be observed. To further elaborate differ-
ences between groups, we depicted a specific overview of
the content of the non-pharmacological treatment in
both arms in figure 2, according to the recommendations
of Perera et al 2007 [35].
For both interventions, manuals and standardized pre-
sentations were created. At baseline and every six
months, all care providers assemble to assess and
enhance the adherence with the treatment protocols.
Experimental intervention group
Patients (eight per group) allocated to the experimental
intervention group attend six therapeutic group sessions
and one group evaluation. During these six sessions
patients aim to improve daily functioning by optimising
their current lifestyle (i.e. physical activity and diet) and
by enhancing self-efficacy to control the consequences of
the disease in everyday life (i.e. activity pacing, pain man-
agement and daily functioning). To enhance patients' self-
efficacy the 5As model of behaviour change counselling is
used, which is an evidence-based approach appropriate
for a broad range of different behaviours and health con-
ditions. The 5As consists of: Assessing patient level of
behaviour, beliefs and motivation; Advising the patient
based upon personal health risks; Agreeing with the
patient on a realistic set of goals; Assisting to anticipate
barriers and develop a specific action plan; and Arranging
follow-up support [36]. The following example might
illustrate the use of the 5As model. A participant wears a
pedometer to elicit his/her physical activity level (A1).
Together with the health care provider, the patient dis-
cusses the outcome (A2) and set a goal to increase the
level of physical activity (A3). Both the health care pro-
vider and the patient must believe the goal is adequate
(A3) and realistic (A4). Consequently, patient and thera-
pist closely monitor the personal goals (A5). In addition
to the self-management programme, patients are also
enrolled in an exercise programme aimed to 1. improve
the quality of movement and 2. implement the learned
exercises in the home situation.
Active control group
Patients enrolled in the active control group, attend two
group sessions (eight patients per group) and are further
monitored through four telephone contacts [37]. As per
with the experimental intervention, the active control
group aims to optimise the patients' current lifestyle (i.e.
physical activity and diet) and to enhance the patients'
self-efficacy to control the disease (i.e. activity pacing,
pain management and daily functioning). Again, all
patients set personal goals on the abovementioned items.
Progress on these personal goals will be monitored by the
health care provider through planned telephone contact.
Patients are asked to self-monitor their own health-status
[37], by filling out activity and dietary diaries.
Health care providers
A total of 14 health care providers (five physiotherapists,
three occupational therapists, five specialized nurses, and
one dietician) are involved in the therapy sessions. All
health care providers are specialized in the management
of patients with musculoskeletal disorders and have expe-
rience in teaching self-management principles to groups.
Moreover, all care providers took the course 'motivational
interviewing'.
The experimental intervention will be provided by one
of three physiotherapists, one of three occupational ther-
apists, one of two specialized nurses and one dietician. In
the active control group, the two group sessions are pro-
vided by one of two physiotherapists and two of three
specialized nurses. The telephone contact will be pro-
vided by the specialized nurses. Assignment of health
care providers to the therapy programs was done on basis
of availability.Hoogeboom et al. BMC Musculoskeletal Disorders 2010, 11:142
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Figure 2 Graphical depiction of the two self-management interventions. Abbreviations: PSK = Patient Specific Complaints, PT = physiotherapist, 
OT = occupational therapist.
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Eligibility assessment 
Baseline assessment 
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Week 1a
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Week 2b
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Measurement of outcomes
Group education on the health care program, diaries and expectations.
Group education on osteoarthritis, pain and medication.
General exercise program.
Group education about physical activity.
Group education on activity pacing.
Recreational activity.
Group based monitoring of personal goals.
Group education on food consumption.
Specific exercise program, based upon the PSK-scores.
Group education on acceptance and helplessness.
Evaluation and setting goals for the future.
Monitoring of personal goals via telephone by specialized nurse.Hoogeboom et al. BMC Musculoskeletal Disorders 2010, 11:142
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Primary outcome
Daily functioning
The primary outcome of the study is the Stanford Health
Assessment Questionnaire (HAQ) Disability Index dur-
ing the first year after treatment [34,38]. The HAQ is an
independent patient-reported outcome questionnaire
containing 20 questions, covering eight domains of activ-
ities of daily living. For each item, there is a four-level
response set that is scored from 0 to 3, with higher scores
indicating more disability (0 = without any difficulty; 1 =
with some difficulty; 2 = with much difficulity; and 3 =
unable to do). Both total scores as well as each of the sub-
scores range from 0 (no disability) to 3 (severe disability).
An improvement of 0.26 points is considered to be clini-
cally relevant between group change [39]. The HAQ has
been found to be more responsive for measuring func-
tioning than the WOMAC questionnaire; a widely used
in hip and knee OA [40].
Secondary outcomes
Health-related quality of life (clinical efficacy)
To assess the efficacy of the interventions on health-
related quality of life (HRQoL) the RAND 36-Item Health
Survey 1.0 (RAND-36) will be used [41]. Scores from the
eight subscales of the RAND-36 will be aggregated into
two summary scores: a Physical Component Summary
(PCS) and a Mental Component Summary (MCS). This
instrument has been translated and validated for use in
Dutch patients [42].
Patients specific complaints (clinical efficacy)
Physical functioning assessed with the patient specific
complaints questionnaire (PSK). The PSK is a patient-
specific questionnaire in which the patient is asked to
select three activities that (s)he perceives as problematic
(activities that can easily be avoided are not allowed) and
scores the severity on a 10 cm visual analogue scale (VAS)
[43].
Fatigue (clinical efficacy)
Fatigue is measured with the "Subjective Fatigue" sub-
scale of the Checklist Individual Strength (CIS) [44]. The
CIS is a self-administered questionnaire assessing 20
items, concerning 4 subscales divided in: subjective expe-
rienced fatigue (8 items), concentration (5 items), motiva-
tion (4 items) and physical activity (3 items). The
outcomes per question are given in a 7-point scale, rang-
ing from the statement 'totally right' to the statement
'totally wrong'. The total score is counted in points with a
range of 1-7 per question and a total score range of 8-56
points. The CIS is a sensitive instrument with good dis-
criminating power and reliability [44].
Health-related quality of life (health economics)
To measure the HRQoL of patients for the purpose of
economic evaluation the EuroQol-5D (EQ-5D) will be
used [45]. This HRQoL instrument will be completed by
the patients and is available in a validated Dutch transla-
tion. The EQ-5D is a generic HRQoL instrument com-
prising five domains: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. The EQ-5D
index is obtained by applying predetermined weights to
the five domains. This index gives a societal-based global
quantification of the patient's health status on a scale
ranging from 0 (death) to 1 (perfect health). The utility
weights captured by these preferences will enable the der-
ivation of the Quality Adjusted Life Years (QALY) for
each intervention and will be used in cost-utility analyses.
Patients will also be asked to rate their overall HRQoL
on a visual analogue scale (EQ- 5D VAS) consisting of a
vertical line ranging from 0 (worst imaginable health sta-
tus) to 100 (best imaginable).
Costs (health economics)
Volumes of care will be measured prospectively using
patient-based diaries (complemented by patient chart
data if necessary). Per arm (intervention and control) full
c o s t - p r i c e s  w i l l  b e  d e t e r m i n e d  u s i n g  a n  a c t i v i t y  b a s e d
costing approach. Productivity losses for patients will be
estimated using a postal questionnaire on a 3 months
recall basis. The friction cost-method will be applied fol-
lowing the Dutch guidelines for cost analysis (Oosten-
brink et al., CVZ 2004). Also travel time to a session or
outpatient clinic and related costs patients make will be
considered (also on the basis of 3 months recall).
The second part of the cost analysis consists of deter-
mining the cost prices for each unit of consumption in
order to use these for multiplying the volumes registered
for each participating patient. The Dutch guidelines for
cost analyses will be used (CVZ, Oostenbrink et al.,
2004). For units of care/resources where no guideline or
standard prices are available real cost prices will be deter-
mined.
Study endpoints
Participants will receive postal questionnaires at baseline,
and at 6, 13, 26, 39 and 52 weeks after the start of the
intervention. The primary endpoint to study the long
term effects of the interventions is the averaged HAQ-
score [34] as obtained from the 6, 26 and 52 week time
points. The 6 week time point will provide a secondary
endpoint for investigating the short term effects of the
interventions. On time points 6, 13, 26, 39 and 52 costs
will be assessed.
Socio-demographic information will be collected at
baseline including age, gender, employment nature and
body mass index. In Table 1 we outlined all outcome
measures that will be collected at baseline and at follow-
up evaluations.
Other outcomes
Since no validated outcome measures are available yet for
the assessment of health status in patients with GOA, we
decided to evaluate effectiveness also with a responderHoogeboom et al. BMC Musculoskeletal Disorders 2010, 11:142
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Table 1: Outcome measures used at baseline and follow-up assessments
Outcome (Instrument) Time Points (weeks)
0 6 13 26 39 52
Daily functioning (HAQ) [34] X X X X X X
HRQoL (RAND-36) [42] X X X X
HRQoL (EuroQol EQ-5d) [45] X X X X X X
Patient specific complaints (PSK) [43] X X X X
Fatigue (CIS-8) [44] X X X X
Physical activity (SQUASH) [48] X X X X
Illness Cognitions (ICQ) [65] X X X X
Patient Global Assessment (PGA) [50] X X X
Self-efficacy (GSES) [51] X X X X
Kinesiophobia (TSK) [66] X X X X
C o s t s X XXXX
Abbreviations: HRQoL = Health related quality of life.
analysis. We developed an adapted version of the OMER-
ACT-OARSI Responder Criteria as the secondary out-
come measure of our study [46]. This composite index
permits presentation of results of symptom modifying
clinical trials in OA based on individual patient responses
(responder yes/no). In this study, patients are considered
responders if at least 3 of the 6 targeted areas (i.e. physical
functioning, pain, fatigue, physical activity, acceptance,
and patient global assessment) improve by ≥ 20% [47]. We
assess the targeted areas with the following secondary
outcome measures: RAND-36-pain, PSK, CIS and
SQUASH, ICQ, PGA (as described below).
Physical activity
The Short QUestionnaire to ASsess Health-enhancing
physical activity (SQUASH) [48] will be used to measure
physical activity. The SQUASH measures habitual physi-
cal activity level and is structured in a way that allows
comparing the results to international physical activity
guidelines. The questions are prestructured into activities
at work, activities to/from work, household activities, lei-
sure-time activities and sports activities. Spearman cor-
relation has shown an overall reproducibility of 0.58 (p <
0.05) for the SQUASH. The SQUASH has been validated
using an accelerometer, the CSA Inc. Activity Monitor
(model AM7164-2.2), showing a Spearman correlation
coefficient between CSA readings and total activity score
of 0.45 (95% CI 0.17-0.66) [48].
Illness cognitions
Illness cognitions (acceptance and helplessness) are mea-
sured using the Illness Cognitions Questionnaire (ICQ).
The ICQ is an 18-item questionnaire measuring three
generic illness cognitions: helplessness, acceptance and
disease benefits. Participants rate the extent to which
they agree with the statements on a 4-point Likert scale,
ranging from 1 (not at all) to 4 (completely). Higher
scores at subscales reflect higher levels of agreement with
that generic illness cognition. The scale has excellent con-
struct and internal validity [49]. In this study we use the
subscales acceptance and helplessness.Hoogeboom et al. BMC Musculoskeletal Disorders 2010, 11:142
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Global perceived improvement
Patient Global Assessment (PGA) is assessed by patients
on a 8-point scale (1 = vastly worsened; 8 = completely
recovered) [50].
Self-efficacy
Self-efficacy is evaluated with the General Self-Efficacy
Scale (GSES) - the Dutch Language Version; a self-admin-
istered questionnaire assessing 10 items, concerning
problems in daily living and the capability to bring up
solutions for these problems [51]. The scores of the ques-
tions are rated on a 4-point scale. Possible responses are
not at all true, hardly true, moderately true and exactly
true yielding a total score between 10 and 40 points. A
higher score represents a higher level of self-efficacy. The
GSES was found to be configurally equivalent across 28
nations, and it forms only one global dimension. High
reliability, stability, and construct validity of the GSES
were confirmed in earlier studies [51].
Randomization, allocation concealment and blinding
Participants included in the study are randomly assigned
to one of the treatment programmes. Restricted random-
ization will be used by randomly varied block sizes (2 to
6) [52]. A computer-generated randomization sequence
table will be produced with random allocation software
[53] by an independent researcher (DJ). Subsequently an
independent person will assign patients to one of the
treatment groups. This person has no information about
the persons included and has no influence on the assign-
ment sequence or on the decision about eligibility of
patients.
Patients and health care providers allocated to the
experimental and active control group will be aware of
the allocated arm, whereas the outcome assessor and data
analysts will be kept blinded to the allocation.
Sample size
For the sample size calculation we used the statistical
package G*power 3.0.10 [54]. We utilized the equation for
sample size required per group using an unpaired t-test to
compare differences between two independent means. To
detect a minimal clinically important change of 0.26
points [39] in mean HAQ scores between both groups,
assuming a SD of: 0.66 (SE*???8N = 0.04*???ξτ271 = 0.66)
[40] with 80% power and a two-sided 5% level, we will
need 102 patients per arm (effect size is 0.26/0.66 = 0.39).
The abovementioned sample size calculation is relevant
for analyses with independent t-tests.
In our analyses, however, we will use the baseline HAQ
as a covariate. By a straightforward generalisation of the
method described in Borm et al [55], it can be shown that
in this case the sample size must be multiplied by (1-(k-
1)ρ)/k - ρB
2 (see note below), where k is the number of fol-
low-up assessments (3 in our case), where ρB is the corre-
lation between the outcome measured at baseline and at
follow-up and where p is the correlation between the fol-
low-up measurements. Although some publications
report test-rest correlation for the HAQ of more than 0.8
(31), there is no direct information about the correlation
that is to be expected in our trial. W e expect ρ B to be
smaller than p  (even within the treatment groups),
because the interventions will be 'between' the baseline
and follow-up assessments. The interventions may not
have the same effect on all patients and therefore
decrease the correlation. When p is between 0.7 and 0.9
and ρB = p-0.2, the sample size can be reduced by a
(design) factor 0.44 to 0.55. For p between 0.8 and 0.9 and
ρB = p-0.1, the sample size can be reduced by a factor 0.38
to 0.44. A trial with 55 patients per treatment group will
then have at least 80% power (when the design factor is
0.55). In the most optimistic scenario, when the design
factor is 0.38, the study has slightly over 90% power.
Finally, as the patients will be treated in groups (cluster)
of approximately eight, the patient numbers have to be
increased by a factor 1+(8 -1)*ICC. For ICC = 0.05, this
leads to 74 patients. In order to compensate for possible
drop-outs (15%), we plan to enrol 85 patients per treat-
ment group.
Note:
When Y = mean(Y1, ...Yk) and the baseline and follow-
up measurements Yi all have standard deviation σ, the
variance of Y is ((1+(k-1)p)/k)σ2, the correlation between
B and Y is k ρB/sqrt(k+(k(k-1) p) and the formula in Borm
et al yields the design factor (1-(k-1)ρ)/k - ρB
2.
Planned data analysis
Study data are entered in Access 2003, exported to the
statistical package STATA v10 stored on a secure network
drive. Five percent of the data will be entered twice to
assess percentage and nature of typing errors. All paper
records are stored in a locked cabinet in an anonymised
format. The researcher will check for any missing data
and will manage this according to the recommendations
of the questionnaires. Descriptive statistics will be used
to determine participant characteristics. Continuous
variables will be reported using means, standard devia-
tions (SD) and inter-quartile ranges when appropriate, if
not median and ranges are shown. For dichotomous/cate-
gorical variables, we will display absolute numbers and
percentages. The primary analysis will be according to
the intention to treat principle.
Clinical efficacy
The primary variable, HAQ during the first year after
treatment, will be analysed with a random effects model
with the HAQ scores after 6, 26 and 52 weeks as depen-
dent variable. The fixed factors will be assessment (6, 26
or 52 weeks), treatment group, sex and baseline value. InHoogeboom et al. BMC Musculoskeletal Disorders 2010, 11:142
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order to account for the group wise treatment and the
repeated measurements, the random effects group and
patient will be included.
HAQ immediately after treatment will be evaluated in a
random effects model with fixed factors treatment group,
sex and baseline value, and random factor group. All
other continuous variables will be analysed in a similar
way. Skewed variables will be transformed before analy-
sis. For dichotomous outcomes, random effects general
linear models with Bernoulli distribution and linear link
function will be used, similar to the ones described for
continuous outcomes.
Changes in effect size over time will be evaluated by
adding the interaction of assessment and treatment group
to the model.
Health economics
The economic evaluation is based on the general princi-
ples of a cost-effectiveness analysis and cost-utility analy-
sis. For the cost-effectiveness analysis we will calculate
the incremental cost-effectiveness ratio (ICER) as cost
per unit improvement on the HAQ. For the cost-utility
analysis we will calculate the ICER as cost per Qaly
gained. This ICER will be evaluated stochastically and
uncertainty will be determined using the bootstrap
method and/or Fieller method. A cost-effectiveness
acceptability curve will be derived that is able to evaluate
efficiency by using different thresholds (Willingness To
Pay) for a QALY. The impact of uncertainty surrounding
deterministic parameters (for example cost-prices) on the
ICER will be explored using one-way sensitivity analyses
on the range of extremes. The economic evaluation is
done along-side the clinical trial and consequently
adheres to the earlier presented design.
Discussion
To date, research on NPT options for OA has mainly
focused upon patients with hip and knee OA. In 2008,
NICE disseminated multiple recommendations for future
OA research based on the research hiatuses they identi-
fied. One of their research questions was: "What are the
benefits of individual and combination OA therapies in
people with multiple joint region pain?". This study will
contribute to the body of evidence on NPT in GOA
patients.
A possible limitation in our study is the limited contrast
in the content of the experimental and control interven-
tion. Both interventions were developed from a clinical
and pragmatic perspective. Since both interventions
should be directly implementable in clinical practice after
study completion, we created two treatment protocols
according to the recommendations outlined in OA guide-
lines and current best-practice. The content of both inter-
ventions is very similar but several critical differences are
apparent such as the mode of delivery, the number of
involved health care providers and the number of group-
sessions. Specific insights in the effectiveness and costs of
these differences will aid health care providers and care
vendors in their decision making for the management of
patients with GOA.
To our knowledge we are the first to define GOA from a
clinical rather than a radiographic perspective, as no con-
sistent clinical useful definition of GOA is available. In
1952, Kellgren and Moore defined GOA as involvement
of multiple joints combined with Heberden's nodule [31].
Since then, multiple definitions of GAO have been used,
for the greater part based on radiological changes. Most
definitions state that GOA involves at least three joints
[31], although this again is questioned [27]. The group of
joints most often incorporated in definitions are the
hands, neck, lower back, knees and hips [7,56,57],
whereas other definitions postulate that the involvement
of atypical joints [25,26] or hallux valgus [25,58] is essen-
tial for GOA. To date, two specific phenotypes of GOA
have been established [28], however, these phenotypes
are far from useful in daily practice as these phenotypes
only represent a very small proportion of patients with
OA-like complaints in multiple joints. Considering the
low feasibility and desirability of obtaining radiographs of
a large number of joint in clinical practice, we believe that
clinical signs and symptoms s h o u l d  a l so  be  t a k e n  i n t o
account in the definition of GOA. Especially, since pain at
multiple joint sites is associated with lower levels of func-
tioning [21,23,59-61], more pain [21,23,59,60] and higher
levels of distress [21,59,62], and complaints rather than
radiographic OA are the main motivation for patients to
engage in therapy. So, for the purpose of this project we
formulated a pragmatic definition of GOA (as described
earlier) based upon literature findings and on the basis of
consensus of several clinicians and health professionals
with experience with patients with GOA.
There is a need for outcome measures to evaluate self-
management interventions [63]. Self-management is
defined as the individual's ability to manage the symp-
toms, treatment, physical and psychosocial consequences
and lifestyle changes inherent i n  l i v i n g  w i t h  a  c h r o n i c
condition [64]. Characteristically, one or more of these
areas are addressed by self-management interventions
[63]. In our study we target physical functioning, pain,
fatigue, physical activity, and acceptance. However, no
comprehensive outcome measure is available to measure
all these different aspects. Mulligan et al (2005) state that
when designing a self-management intervention, it is
important to be clear about what the intervention is
designed to achieve, in what areas it is likely to have an
effect, and to choose outcome measures accordingly [63].
Therefore, we decided to include a responder analysis -
derived from the OMERACT-OARSI responder criteria
[46] - as one of the secondary measures in our analysisHoogeboom et al. BMC Musculoskeletal Disorders 2010, 11:142
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that specifically evaluates those areas we aim to address.
In a future publication we intend to evaluate and discuss
this method of assessing self-management interventions.
In conclusion, this study will provide additional insights
in the effectiveness of non-pharmacological interventions
for GOA. The publication of our study protocol enables
future readers to compare what was originally intended
with what was actually done, thus preventing both "data
dredging" and post-hoc revisions of study aims.
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